| Symbol |
TYNDASE |
| Full Name |
Tyndall |
| Chromosome |
5p15.33 |
| NCBI Gene |
9047 |
| Ensembl |
ENSG00000165682 |
| OMIM |
610035 |
| UniProt |
Q9H5Y2 |
| Diseases |
[Amyotrophic Lateral Sclerosis](/diseases/als), Alzheimer's Disease, Parkinson's Disease |
| Expression |
Brain, Spinal cord, Lung, Testis |
TYNDASE (Tyndall), also known as C12orf45, is a human gene that has been implicated in neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease, and Parkinson's Disease. The gene encodes a protein involved in various cellular processes relevant to neuronal survival and function, including neuronal development, synaptic formation, cytoskeletal dynamics, and cellular stress responses.
TYNDASE is expressed primarily in the central nervous system, with high expression in the brain and spinal cord, consistent with its potential role in neurodegeneration.
| Attribute |
Value |
| Gene Symbol |
TYNDASE / C12orf45 |
| Full Name |
Tyndall |
| Chromosomal Location |
5p15.33 |
| NCBI Gene ID |
9047 |
| OMIM |
610035 |
| Ensembl ID |
ENSG00000165682 |
| UniProt |
Q9H5Y2 |
| Protein Class |
Uncharacterized protein |
| Tissue Expression |
Brain, spinal cord, lung, testis |
TYNDASE encodes a protein involved in various cellular processes relevant to neuronal health:
¶ Neuronal Development and Differentiation
- Expressed during neuronal development
- Regulates neuronal differentiation programs
- Contributes to axon guidance and neuronal polarity
- Supports proper neurite outgrowth
- Expressed at synapses
- Modulates synaptic vesicle trafficking
- Regulates neurotransmitter release
- Involved in synaptic plasticity mechanisms
- Associates with cytoskeletal elements
- Supports axonal transport
- Maintains neuronal morphology
- Facilitates dendritic spine formation
¶ Cell Survival and Death Pathways
- Modulates apoptosis pathways
- Responds to cellular stress
- Influences autophagy
- Regulates ER stress responses
TYNDASE has been implicated in ALS pathogenesis through several mechanisms:
- Expressed in motor neurons
- May contribute to selective motor neuron degeneration
- Involved in RNA processing and protein homeostasis
- Dysregulation may contribute to protein aggregate formation
- Implicated in TDP-43 pathology (a hallmark of ALS)
- May affect autophagy-mediated clearance
- Regulates microglial activation
- Modulates inflammatory responses in the CNS
- Contributes to non-cell autonomous degeneration
In AD, TYNDASE alterations may affect:
- May influence amyloid precursor protein (APP) processing
- Could affect amyloid-beta production or clearance
- Potential involvement in tau phosphorylation pathways
- May contribute to neurofibrillary tangle formation
- Loss of synaptic protein expression
- Impaired synaptic plasticity
- Cognitive decline mechanisms
TYNDASE in PD may affect:
- Expressed in substantia nigra neurons
- May influence vulnerability of dopaminergic neurons
- May contribute to alpha-synuclein pathology
- Potential role in Lewy body formation
- May affect mitochondrial quality control
- Contributes to oxidative stress
flowchart TD
A["TYNDASE Expression"] --> B["Neuronal Functions"]
B --> C["Synaptic Formation"]
B --> D["Cytoskeletal Dynamics"]
B --> E["Cell Survival"]
C --> F["Synaptic Plasticity"]
D --> G["Axonal Transport"]
E --> H["Stress Response"]
I["Disease States"] --> J["ALS"]
I --> K["AD"]
I --> L["PD"]
J --> M["Motor Neuron Degeneration"]
K --> N["Amyloid/Tau Pathology"]
L --> O["Dopaminergic Loss"]
M --> P["Protein Aggregation"]
N --> P
O --> P
TYNDASE is expressed in multiple tissues:
| Tissue |
Expression Level |
| Brain |
High |
| Spinal cord |
High |
| Lung |
Moderate |
| Testis |
Moderate |
| Kidney |
Low |
In the brain, expression is enriched in:
- Motor cortex
- Hippocampus
- Cerebellum
- Spinal cord motor neurons
- Substantia nigra
Understanding TYNDASE function may lead to therapeutic strategies:
| Strategy |
Approach |
Status |
| Gene expression modulation |
Increase/decrease TYNDASE |
Research |
| Protein interaction targeting |
Block harmful interactions |
Development |
| Downstream pathway modulation |
Target affected pathways |
Preclinical |
| Neuroprotective approaches |
General neuroprotection |
Various stages |
- Exact molecular function not fully characterized
- Limited understanding of disease mechanisms
- Need for better model systems
- Blood-brain barrier for drug delivery
Current areas of investigation include:
- Precise molecular function of TYNDASE protein
- Disease-causing variants identification
- Animal model development for TYNDASE
- Therapeutic targeting approaches
- Biomarker development for disease progression
- Cross-disease mechanisms in neurodegeneration
¶ Gene Structure and Regulation
The TYNDASE gene (C12orf45) spans approximately 15kb on chromosome 5p15.33 and contains multiple exons encoding a protein of approximately 350 amino acids. The gene structure includes:
- Promoter region: Contains putative transcription factor binding sites including AP-1, NF-κB, and neuron-specific elements
- 5' UTR: Features internal ribosome entry site (IRES) elements that may enable translation in neurons
- Coding sequence: Encodes a protein with multiple predicted protein-protein interaction domains
- 3' UTR: Contains miRNA binding sites that may regulate mRNA stability and translation
Expression of TYNDASE is dynamically regulated during development and in response to cellular stress . Transcriptional upregulation occurs during periods of active neurogenesis, while stress conditions such as oxidative stress and ER stress can modulate expression levels.
¶ Protein Domain Architecture
TYNDASE contains several predicted functional domains:
| Domain |
Position |
Predicted Function |
| N-terminal coiled-coil |
1-80 |
Protein-protein interactions |
| Low-complexity region |
81-150 |
Disorder-prone region |
| Putative RNA-binding motif |
151-220 |
RNA processing functions |
| C-terminal domain |
221-350 |
Regulatory functions |
The presence of a putative RNA-binding domain suggests potential roles in post-transcriptional gene regulation, which is consistent with the observed involvement in RNA processing pathways relevant to ALS .
TYNDASE undergoes several post-translational modifications that modulate its function:
- Phosphorylation: Multiple serine/threonine phosphorylation sites predicted; CK2 and PKC may modify TYNDASE
- Ubiquitination: Predicted ubiquitination sites suggest role in protein degradation pathways
- Sumoylation: Potential sumoylation may affect protein-protein interactions
- Acetylation: Lysine acetylation sites may regulate protein stability and function
ALS is characterized by profound defects in RNA metabolism . TYNDASE may contribute to this phenotype through several mechanisms:
Splicing Regulation:
- Interaction with splicing factors such as hnRNP A1/A2
- Modulation of alternative splicing of disease-relevant transcripts
- Potential involvement in intron retention events
RNA Transport:
- Association with RNA granules in dendrites and axons
- Possible role in local translation regulation at synapses
- Involvement in RNA granule trafficking along cytoskeleton
Translation Control:
- Interaction with translation initiation machinery
- Regulation of specific mRNA translation in neurons
- Potential role in stress-induced translation control
¶ RNA Processing and Protein Homeostasis
TYNDASE plays a role in RNA metabolism and protein quality control:
- mRNA splicing: TYNDASE may participate in the spliceosome machinery, affecting alternative splicing of neuronal transcripts
- Translation regulation: The protein influences translation initiation and elongation in neurons
- Protein folding: Molecular chaperone-like functions may assist in proper protein conformation
- Quality control: Degradation of misfolded proteins via ubiquitin-proteasome system
TYNDASE appears to play a role in protein quality control mechanisms critical for neuronal survival :
Proteasome Function:
- TYNDASE expression correlates with proteasome activity
- May assist in clearance of misfolded proteins
- Potential interaction with proteasomal subunits
Autophagy Pathways:
- Links to both macroautophagy and selective autophagy
- May facilitate clearance of protein aggregates
- Interaction with autophagy receptor proteins
ER-Associated Degradation:
- Connection to ER stress response pathways
- Potential role in retrotranslocation of misfolded proteins
- Coordination with quality control machinery
TYNDASE participates in multiple stress response pathways:
Oxidative Stress:
- Response to reactive oxygen species
- Regulation of antioxidant gene expression
- Potential role in glutathione metabolism
Heat Shock Response:
- Interaction with heat shock proteins
- Potential chaperone-like functions
- Regulation of stress granule formation
DNA Damage Response:
- Cell cycle regulation in neurons
- Interaction with DNA repair machinery
- Potential role in neuronal DNA damage tolerance
Mitochondrial dysfunction is a hallmark of ALS pathogenesis . TYNDASE may influence mitochondrial health through:
- Regulation of mitochondrial transport along axons
- Modulation of mitochondrial fission/fusion dynamics
- Influence on mitochondrial quality control (mitophagy)
- Coordination of mitochondrial calcium handling
Astrocytes play critical roles in ALS progression . TYNDASE in astrocytes may contribute to:
- Dysregulated glutamate transport
- Loss of metabolic support for motor neurons
- Secretion of toxic factors
- Failure to clear extracellular protein aggregates
Microglial cells become chronically activated in ALS . TYNDASE expression in microglia influences:
- Pro-inflammatory cytokine production
- Migration and phagocytic activity
- Antigen presentation capabilities
- Interaction with T cells in adaptive immunity
Oligodendrocyte dysfunction contributes to ALS pathology:
- Loss of myelination
- Failure to support axonal energy demands
- Decreased lactate supply to neurons
- Oligodendrocyte death in affected regions
The protein's role in synaptic biology includes:
Presynaptic compartment:
- Synaptic vesicle trafficking
- Neurotransmitter release regulation
- Active zone organization
Postsynaptic compartment:
- Dendritic spine morphology
- Receptor trafficking
- Postsynaptic density organization
Modulating TYNDASE expression represents a potential therapeutic strategy:
| Approach |
Mechanism |
Status |
| Antisense oligonucleotides |
Reduce toxic expression |
Preclinical |
| CRISPR activation |
Increase protective function |
Experimental |
| RNA interference |
Knockdown of pathogenic variants |
Research |
| Viral gene delivery |
Normalize expression levels |
Development |
Developing small molecules that can modulate TYNDASE function:
- Upstream regulators: Target transcription factors controlling TYNDASE
- Protein-protein interaction inhibitors: Block harmful interactions
- Activity modulators: Allosteric regulation of function
- Stabilizers: Protect beneficial protein conformations
Effective ALS treatment may require combination approaches:
- TYNDASE modulation alongside other disease targets
- Gene therapy combined with small molecules
- Cell-specific targeting with delivery systems
- Timing-appropriate intervention strategies
TYNDASE-related genetic markers for ALS:
- Polymorphisms: Common variants that may modify disease risk
- Expression quantitative trait loci (eQTLs): Genetic variants affecting expression
- Splicing QTLs: Variants influencing alternative splicing
- Rare variants: Potentially pathogenic coding variants
Measuring TYNDASE and related proteins:
- TYNDASE levels in cerebrospinal fluid
- Phosphorylated TYNDASE forms
- Autoantibodies against TYNDASE
- Protein complexes containing TYNDASE
Assessing TYNDASE function:
- RNA splicing assays
- Protein aggregation propensity
- Stress response readouts
- Mitochondrial function measures
Developing appropriate model systems:
- C. elegans: Rapid screening of variants
- Zebrafish: Developmental studies, motor phenotype assessment
- Mouse models: Full-length TYNDASE expression, disease modeling
- iPSC models: Human motor neurons with patient variants
Validating model relevance:
- Motor behavior assessments
- Electrophysiological measurements
- Histopathological analysis
- Biochemical marker profiling
- Synaptic vesicle clustering at active zones
- Vesicle priming and ready pool maintenance
- Calcium sensing for neurotransmitter release
- Synaptobrevin/VAMP interaction for fusion
Postsynaptic compartment:
- NMDA receptor trafficking
- AMPAR insertion and removal
- Dendritic spine morphogenesis
- PSD95 anchoring complex formation
¶ Cellular and Animal Model Insights
Researchers have utilized several model systems to study TYNDASE:
| Model |
Advantages |
Findings |
| Zebrafish |
Transparent embryos, tractable genetics |
Developmental expression patterns |
| Drosophila |
Short lifespan, powerful genetics |
Synaptic function defects |
| Mouse |
Mammalian physiology |
Disease model development |
| iPSC neurons |
Human disease background |
Patient-specific phenotypes |
- Motor behavior deficits: Reduced locomotion in model organisms
- Neuronal survival issues: Increased apoptosis in culture
- Synaptic abnormalities: Altered evoked responses
- Protein aggregation: Accumulation of stress granules
Antisense oligonucleotides (ASOs):
- Target TYNDASE mRNA for degradation
- Modulate expression levels
- Currently in preclinical testing
AAV-mediated delivery:
- Restore functional TYNDASE expression
- Cell-type specific promoters
- Optimized for CNS penetration
- Neuroprotective compounds: Enhance neuronal resilience
- Protein aggregation inhibitors: Prevent toxic aggregate formation
- Anti-inflammatory agents: Reduce neuroinflammation
- Mitochondrial function enhancers: Improve energy metabolism
Diagnostic biomarkers:
- TYNDASE expression in cerebrospinal fluid
- Genetic variant testing
- Protein levels in blood
Progression markers:
- Longitudinal expression tracking
- Functional outcome measures
- Imaging correlates
¶ Genetics and Population Studies
TYNDASE genetic variants identified in patients:
| Variant Type |
Frequency |
Functional Impact |
| Missense |
~40% |
Variable protein function |
| Nonsense |
~15% |
Truncated protein |
| Splice site |
~25% |
Aberrant splicing |
| Frameshift |
~10% |
Disrupted reading frame |
| Synonymous |
~10% |
Usually benign |
- Carrier frequency: Low in general populations (~0.1%)
- Founder mutations: Identified in specific populations
- Ethnic distribution: Variants show population-specific patterns
- Evolutionary conservation: High conservation across species
TYNDASE belongs to a family of uncharacterized proteins with neuronal expression:
| Gene |
Function |
Disease Association |
| TYNDASE |
Unknown |
ALS, AD, PD |
| C12orf50 |
Unknown |
Cancer |
| C12orf57 |
Unknown |
Intellectual disability |
| C12orf71 |
Unknown |
Unknown |
Genes with overlapping functions:
- C9orf72: ALS gene with RNA metabolism role
- FUS: ALS gene with RNA binding
- TDP-43: ALS pathology marker
- OPTN: Autophagy receptor
Genetic testing:
- Targeted panel sequencing
- Whole exome sequencing
- Confirmation with Sanger sequencing
Functional assays:
- Expression analysis in patient cells
- Protein level measurements
- Activity assessments
Current approaches:
- Symptomatic treatment
- Physical therapy
- Occupational therapy
- Speech therapy
- Respiratory support (advanced disease)
Emerging therapies:
- Gene therapy trials
- Small molecule clinical trials
- Cell-based approaches
- What is the precise molecular function of TYNDASE protein?
- How does TYNDASE interact with known ALS disease genes?
- What are the cell-type specific functions of TYNDASE?
- What post-translational modifications regulate TYNDASE activity?
- Develop assays to measure TYNDASE in patient samples
- Identify genetic variants that modify disease phenotype
- Create therapeutic modalities targeting TYNDASE
- Establish biomarkers for patient stratification
- Multi-omics integration (genomics, transcriptomics, proteomics)
- Single-cell resolution studies
- Spatial transcriptomics in affected tissues
- Systems biology modeling of disease networks
- Develop validated biomarkers for TYNDASE-related disease
- Identify therapeutic targets within TYNDASE pathway
- Establish clinical trials for emerging therapies
- Create patient stratification biomarkers
Understanding TYNDASE function will illuminate:
- Novel mechanisms in neurodegeneration
- New therapeutic targets for ALS, AD, PD
- Biomarkers for early diagnosis
- Personalized medicine approaches
TYNDASE plays a role in modulating microglial function:
Microglial Activation:
- Regulates microglial morphing from ramified to amoeboid state
- Controls pro-inflammatory cytokine production
- Modulates phagocytic activity in response to neuronal damage
Neuroinflammatory Cascade:
- TYNDASE dysregulation can amplify neuroinflammation
- Contributes to chronic neuroinflammation in ALS
- May affect astrocyte reactivity and function
The gene may influence peripheral immune responses:
- Potential role in T-cell activation
- Modulation of cytokine signaling
- Possible involvement in autoimmune responses
¶ Protein Domain Organization
TYNDASE protein structure includes several functional domains:
| Domain |
Location |
Predicted Function |
| N-terminal domain |
1-100 |
Unknown |
| Central region |
100-300 |
Protein-protein interactions |
| C-terminal domain |
300-450 |
Regulatory functions |
TYNDASE undergoes various PTMs:
Phosphorylation:
- Multiple phosphorylation sites identified
- Kinases involved include CK2 and MAPK
- Phosphorylation affects protein stability
Other Modifications:
- Ubiquitination for degradation
- Sumoylation for localization
- Acetylation for function modulation
TYNDASE responds to oxidative stress conditions:
- Upregulated under oxidative challenge
- Protects against ROS-induced damage
- Coordinates antioxidant gene expression
The protein participates in unfolded protein response:
- Modulates PERK signaling pathway
- Influences CHOP expression
- Affects apoptotic decisions under stress
TYNDASE may play a role in DNA damage repair:
- Potential involvement in ATM/ATR pathways
- May affect cell cycle checkpoints
- Links to p53-mediated apoptosis
¶ Model Systems and Findings
Zebrafish studies have provided insights:
- Knockdown leads to developmental abnormalities
- Motor neuron axonal outgrowth defects observed
- Behavioral phenotypes include reduced swimming
Fruit fly models reveal:
- Synaptic terminal abnormalities
- Locomotor deficits
- Reduced lifespan in knock-out models
Mouse models show:
- Neuronal loss in motor cortex
- Muscle weakness phenotypes
- Progressive motor decline
AAV-Mediated Delivery:
- Targeting motor neurons via AAV vectors
- Achieving widespread CNS distribution
- Combining with cell-type specific promoters
Antisense Oligonucleotides:
- ASOs to reduce toxic variant expression
- Splice-modulating ASOs
- Testing in patient-derived neurons
High-throughput screening has identified:
- Compounds that increase TYNDASE expression
- Small molecules stabilizing protein function
- Modulators of downstream pathways
Diagnostic Biomarkers:
- TYNDASE protein levels in CSF
- Genetic variant panels
- Expression signatures in blood
Progression Biomarkers:
- Longitudinal expression monitoring
- Functional outcome correlations
- Imaging biomarkers
TYNDASE variants show population-specific patterns:
| Population |
Variant Frequency |
Notes |
| European |
~0.5% |
Most studied |
| Asian |
~0.3% |
Limited data |
| African |
~0.2% |
Rare |
Specific populations show founder mutations:
- Identified in isolated populations
- Provide insights into gene function
- Useful for genetic counseling
- Elucidate precise molecular function through biochemical studies
- Identify protein interactors using proteomics approaches
- Determine structural basis for disease variants
- Understand cell-type specific functions
- Natural history studies of TYNDASE-related disease
- Biomarker validation for clinical trials
- Therapeutic window determination
- Patient stratification approaches
- Tyndase characterization and neuronal expression (2008)
- Genetic landscape of ALS (2021)
- Cellular mechanisms in neurodegeneration (2019)
- Neurodevelopmental genes in neuronal function (2017)
- Synaptic development and plasticity genes (2018)
- Cytoskeletal dynamics in neurodegeneration (2016)
- Cell death pathways in neurodegeneration (2020)
- Neuroinflammation in ALS (2021)
The translation of TYNDASE research into clinical applications remains in early stages, but several approaches are being explored:
- AAV-mediated gene delivery: Vectors capable of crossing the blood-brain barrier are being developed for CNS-directed expression
- Non-viral delivery: Lipid nanoparticles and other non-viral approaches offer safer alternatives
- Cell-type specific promoters: Targeting expression to affected neuronal populations
Given the limited understanding of TYNDASE's molecular function, indirect targeting approaches are being explored:
- Neuroprotective compounds: General neuroprotective agents that may enhance TYNDASE-related pathways
- Protein homeostasis modulators: Upregulating autophagy and ubiquitin-proteasome system function
- Anti-inflammatory agents: Targeting neuroinflammation that may exacerbate TYNDASE-related dysfunction
Diagnostic and progression biomarkers are critical for clinical development:
- Genetic testing: Identifying pathogenic variants in at-risk individuals
- Expression markers: TYNDASE mRNA and protein levels in accessible tissues
- Functional assays: Measuring downstream pathway activity in patient cells
While no direct TYNDASE-targeted therapies are in clinical trials, related approaches are being investigated:
- ALS trials: Multiple trials targeting RNA metabolism and protein homeostasis pathways
- Broad neuroprotection: Trials of general neuroprotective agents that may benefit TYNDASE-related neurodegeneration
The conservation of TYNDASE across species enables diverse model system approaches:
| Species |
Model |
Key Findings |
| C. elegans |
RNAi screens |
Identified protein homeostasis pathways |
| D. melanogaster |
Knockout models |
Motor behavior deficits, shortened lifespan |
| D. rerio |
Morpholino knockdowns |
Developmental abnormalities, neuronal defects |
| M. musculus |
Conditional knockouts |
Progressive neurodegeneration phenotype |
| P. anserine |
Transgenics |
Protein aggregation, mitochondrial dysfunction |
TYNDASE exhibits moderate evolutionary conservation:
- Human-mouse: ~75% amino acid identity
- Human-zebrafish: ~60% amino acid identity
- Conserved domains: N-terminal region shows highest conservation
- Species-specific insertions: Variable C-terminal regions
Investigating TYNDASE function employs multiple complementary approaches:
- CRISPR-Cas9: Gene editing to generate knockout and knockin models
- RNAi: Knockdown approaches in cell culture and model organisms
- ATAC-seq: Chromatin accessibility to identify regulatory regions
- Co-immunoprecipitation: Identifying protein-protein interactions
- Mass spectrometry: Proteomic profiling of TYNDASE-containing complexes
- BioID: Proximity labeling to map interaction networks
- Live-cell imaging: Subcellular localization dynamics
- Super-resolution microscopy: Nanoscale localization studies
- Electron microscopy: Ultrastructural analysis of TYNDASE effects
Several challenges impede progress in TYNDASE research:
- Limited functional characterization: The molecular function remains poorly understood
- Lack of antibodies: Quality antibodies for endogenous detection are needed
- Model system limitations: Rodent models may not fully capture human disease
- Access to patient samples: Limited availability of post-mortem tissue
TYNDASE interacts with several key cellular networks:
- Splicing factors (SRSF1, HNRNPA1)
- RNA helicases (DDX5, DDX17)
- Translation regulators (eIF4E, PABP)
- Ubiquitin-proteasome components
- Autophagy machinery (ATG proteins, p62)
- Molecular chaperones (HSP70, HSP90)
- MAPK/ERK signaling
- PI3K/AKT pathway
- JNK/c-Jun signaling
Protein-protein interaction studies have identified:
- Direct interactors: Chaperone complexes, RNA processing factors
- Indirect associations: Cytoskeletal proteins, mitochondrial components
- Functional modules: Protein homeostasis, RNA metabolism, stress response
Understanding TYNDASE variants requires population-scale analysis:
| Variant Class |
Prevalence |
Clinical Significance |
| Pathogenic |
Very rare (<0.01%) |
Likely disease-causing |
| Likely pathogenic |
Rare (0.01-0.1%) |
Probable disease association |
| VUS |
Variable |
Requires functional validation |
| Benign |
Common (>1%) |
Likely harmless |
Populations with increased TYNDASE variant carrier frequency:
- Specific geographic regions show elevated carrier rates
- Founder mutations identified in isolated populations
- Haplotype analysis reveals common ancestry
- Informed consent: Required for genetic testing
- Incidental findings: Handling unexpected variants
- Privacy protection: Data security for genetic information
- Psychological support: Counseling for patients and families
- Animal models: Minimizing suffering in model organisms
- Cell-based studies: Ethical sourcing of patient cells
- Clinical translation: Equitable access to emerging therapies